Roldan CJ et al., 2022-11-03: Single-blind randomized phase 2 trial at a US cancer centre in 60 patients with treatment-related oral mucositis pain, randomizing to three methylene blue oral rinse concentrations plus conventional therapy or conventional therapy alone. All three methylene blue arms reduced pain scores and oral function burden at day 2 with no serious adverse events.
Compared with those who received CTx alone, those who received MB had a significant reduction of pain scores at day 2 of treatment
Roldan CJ et al., 2022-11-03: Single-blind randomized phase 2 trial at a US cancer centre in 60 patients with treatment-related oral mucositis pain, randomizing to three methylene blue oral rinse concentrations plus conventional therapy or conventional therapy alone. All three methylene blue arms reduced pain scores and oral function burden at day 2 with no serious adverse events. Study type: randomized, single-blind, 4-arm phase 2 trial. N=60 completed (arms 15/14/15/16). Country: United States (MD Anderson Cancer Center). Dose/route: methylene blue oral rinse 0.025%, 0.05% or 0.1%, every 6 hours for 2 days; safety to 30 days. Comparator: conventional therapy alone. Results: pain reduction day 2 of 5.2, 4.5 and 5.15 points versus conventional therapy; oral function burden improved; no serious adverse events; 8 patients reported burning with first dose and 1 discontinued. Funding: NCI P30 CA016672. Conflicts: the lead author 'is currently applying for a patent on the use of Methylene blue for oral pain in mucositis associated to cancer therapy'. Registration NCT03469284. Symptom control, not anti-tumour. Study type: randomized trial.
